Previous 10 | Next 10 |
Summary Viatris has seen a disappointing performance since its 2019 mega tie-up. Sales and EBITDA have fallen a bit, as leverage has fallen a bit further. The overall performance has been disappointing, but valuations have compressed further, leaving me wondering why recent deals ha...
Last December, Viatris (NASDAQ: VTRS) and Kindeva Drug Delivery lost in court against AstraZeneca (NASDAQ: AZN) over a patent dispute regarding one of the latter's patents for its asthma and chronic obstructive pulmonary disease (COPD) treatment Symbicort. This extended the la...
Viatris Inc. (VTRS) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 06:00 PM ET Company Participants Michael Goettler - CEO Rajiv Malik - President Jeffrey Nau - Head, Eye Care Conference Call Participants Chris Schott - JPMorgan Presen...
Summary Dividend investing can work over time and anyone can create an ever growing passive income stream. My year over year progress is moving at a nice clip. Grand total for 2022 dividends: $14,496.97. The beginning of every month is exciting for...
Summary SPDV is an ETF holding five S&P 500 stocks in each sector in equal weight. Constituents are selected based on dividend yield and free cash flow. Valuation and dividend growth metrics look good. Quality and past performance are just average. This dividend ...
Nyxol ® Eye Drops Potentially Offer Differentiated Mechanism of Action to Treat Age-Related Blurry Near Vision Launch of Presbyopia Phase 3 Program Supported by Positive Clinical Results that Demonstrated Durable Efficacy and Favorable Safety Profile FARMING...
Summary In today's article, we provide a fourth-quarter update on our Inverse Jim Cramer strategy analyzing the performance, or lack thereof, behind his top-mentioned stock recommendations. This was yet another quarter in which we showed that inverting Jim Cramer's highest conviction pi...
The past year was a rough one for the stock market, with the S&P 500 falling 19.4% in 2022. But the result of this downturn is that investors now have some attractive stock-buying opportunities. For instance, share prices of Viatris (NASDAQ: VTRS) , General Motors (NYSE:...
Viatris ( NASDAQ: VTRS ) on Tuesday formally closed its acquisition of Oyster Point Pharma and Famy Life Sciences , and as a result established the Viatris ( VTRS ) Eye Care Division. Viatris ( VTRS ) paid ~$415M in cash upfront for Oyster Point plus a plus a cont...
Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division PR Newswire Division Combines Oyster Point Pharma's Eye Care Expertise with Famy Life Science's Phase III-ready Pipeline and Lays Foundation for Viatris to Bec...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...